Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Donald Trump’s threat to impose a 50 per cent tariff on all exports from the EU would deliver a hammer blow to key ...

Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...